Search
Keros Therapeutics Inc
KROSAdd to Watchlist
11.260USD
+0.380+3.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
220.06MMarket Cap
LossP/E TTM
More Details of Keros Therapeutics Inc Company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Keros Therapeutics Inc Info
Ticker SymbolKROS
Company nameKeros Therapeutics Inc
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Number of employees169
Security typeOrdinary Share
Fiscal year-endApr 08
Address1050 Waltham Street, Suite 302
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16173146297
Websitehttps://www.kerostx.com/
Ticker SymbolKROS
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Company Executives of Keros Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
12.34K
+65.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
7.14K
--
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
5.71K
+79.13%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
4.52K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
12.34K
+65.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
7.14K
--
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
5.71K
+79.13%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
FAQs
Who are the top five shareholders of Keros Therapeutics Inc?
The top five shareholders of Keros Therapeutics Inc are: Dr. Jasbir Seehra, Ph.D.
How many institutions hold shares of Keros Therapeutics Inc (KROS)?
As of 2026Q1, 427 institutions hold shares of Keros Therapeutics Inc, with a combined market value of approximately 22.62M, accounting for 114.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -32593016.00.